Lindone (Pregabalin)

• Pregabalin is indicated for several neurological and pain‑related conditions where abnormal neuronal excitability is a key factor.
• Partial onset seizures: helps reduce the frequency of seizure episodes in patients with epilepsy.
• Diabetic peripheral neuropathy: alleviates pain associated with nerve damage in diabetes.
• Postherpetic neuralgia: diminishes lingering nerve pain after shingles.
• Fibromyalgia: lessens widespread musculoskeletal pain and improves functional status.
• Generalized anxiety disorder: reduces anxiety symptoms in adults.

• Pregabalin binds selectively to the α2‑δ subunit of voltage‑gated calcium channels in the central nervous system. This binding decreases calcium influx into presynaptic neurons, which in turn reduces the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P, leading to diminished neuronal hyper‑excitability and pain signaling.

Pregabalin may cause a range of adverse reactions, from mild to severe. Monitoring and reporting are essential for patient safety.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Somnolence: increased sleepiness or fatigue.
• Peripheral edema: swelling of the hands, feet, or ankles.
• Weight gain: gradual increase in body weight.
• Blurred vision: temporary visual disturbances.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Angioedema: rapid swelling of face, lips, tongue, or throat.
• Severe rash or Stevens‑Johnson syndrome: extensive skin eruptions.
• Suicidal thoughts: emergence of depressive or suicidal ideation.
• Myopathy: muscle weakness or pain.
• Acute renal failure: sudden loss of kidney function.
• Anaphylaxis: severe allergic reaction with breathing difficulty.

• Pregabalin requires careful consideration of patient history and concurrent conditions before initiation.
• Renal impairment: dose adjustment may be needed in patients with reduced kidney function.
• History of substance misuse: monitor for signs of dependence or abuse.
• Pregnancy and lactation: weigh potential benefits against unknown risks.
• Elderly patients: start with lower doses due to increased sensitivity.
• Concomitant CNS depressants: avoid excessive sedation when combined with alcohol or opioids.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Pregabalin can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Opioids: combined use may cause profound respiratory depression.
• Central nervous system depressants (e.g., benzodiazepines, barbiturates): increase risk of severe sedation and impaired coordination.
• Anticholinergic agents: may exacerbate cognitive impairment.

Moderate Interactions (Monitor Closely)

• Alcohol: can enhance dizziness and somnolence.
• ACE inhibitors or ARBs: may increase risk of peripheral edema.
• Antidiabetic drugs: monitor blood glucose as pregabalin may affect glycemic control.